<DOC>
	<DOC>NCT00282997</DOC>
	<brief_summary>To evaluate the safety of pregabalin in patients with fibromyalgia.</brief_summary>
	<brief_title>A Safety Study Of Pregabalin In Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites. Patients must complete the doubleblind study. Patients who experienced a serious adverse event during the previous fibromyalgia study, which was determined to be related to the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>